JP2020128412A5 - - Google Patents

Download PDF

Info

Publication number: JP2020128412A5
Authority: JP; Japan
Prior art keywords: weight; ethyl; subject; composition; composition according
Prior art date: 2020-05-13
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

JP2020084402A

Other languages

English (en)

Japanese (ja)

Other versions

JP7136526B2 (ja

JP2020128412A (ja

Filing date

2020-05-13

Publication date

2022-07-20

2020-05-13 Application filed filed Critical

2020-08-27 Publication of JP2020128412A publication Critical patent/JP2020128412A/ja

2022-07-20 Publication of JP2020128412A5 publication Critical patent/JP2020128412A5/ja

2022-09-13 Application granted granted Critical

2022-09-13 Publication of JP7136526B2 publication Critical patent/JP7136526B2/ja

Status Active legal-status Critical Current

2031-03-04 Anticipated expiration legal-status Critical

Links

239000000203 mixture Substances 0.000 claims description 13
229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 9
238000002560 therapeutic procedure Methods 0.000 claims description 3
229920000064 Ethyl eicosapentaenoic acid Polymers 0.000 claims 8
SSQPWTVBQMWLSZ-AAQCHOMXSA-N ethyl (5Z,8Z,11Z,14Z,17Z)-icosapentaenoate Chemical compound CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC SSQPWTVBQMWLSZ-AAQCHOMXSA-N 0.000 claims 8
DSQFSRAJFCOGKA-GKFVBPDJSA-N (5z,8z,11z,14z)-2-ethylicosa-5,8,11,14-tetraenoic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCC(CC)C(O)=O DSQFSRAJFCOGKA-GKFVBPDJSA-N 0.000 claims 5
208000024172 Cardiovascular disease Diseases 0.000 claims 4
239000002775 capsule Substances 0.000 claims 3
208000010125 myocardial infarction Diseases 0.000 claims 3
CLWMCOKPVIXYQL-UHFFFAOYSA-N 2-ethyldocosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCCC=CC=CC=CC=CC=CC=C(CC)C(O)=O CLWMCOKPVIXYQL-UHFFFAOYSA-N 0.000 claims 2
206010014486 Elevated triglycerides Diseases 0.000 claims 2
235000020669 docosahexaenoic acid Nutrition 0.000 claims 2
MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims 2
YBKSMWBLSBAFBQ-UHFFFAOYSA-N ethyl arachidate Chemical compound CCCCCCCCCCCCCCCCCCCC(=O)OCC YBKSMWBLSBAFBQ-UHFFFAOYSA-N 0.000 claims 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
RRRQMBRDGQTXCC-UHFFFAOYSA-N ethyl nonadeca-2,4,6,8,10-pentaenoate Chemical compound CCCCCCCCC=CC=CC=CC=CC=CC(=O)OCC RRRQMBRDGQTXCC-UHFFFAOYSA-N 0.000 claims 2
GIODNRPAARSHAH-UHFFFAOYSA-N ethyl octadeca-2,4,6,8-tetraenoate Chemical compound CCCCCCCCCC=CC=CC=CC=CC(=O)OCC GIODNRPAARSHAH-UHFFFAOYSA-N 0.000 claims 2
229960002600 icosapent ethyl Drugs 0.000 claims 2
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 6
238000005259 measurement Methods 0.000 description 2
238000000034 method Methods 0.000 description 2
XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
108010028554 LDL Cholesterol Proteins 0.000 description 1
RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
229960005370 atorvastatin Drugs 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
229960000672 rosuvastatin Drugs 0.000 description 1
BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
229960002855 simvastatin Drugs 0.000 description 1
RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1

JP2020084402A 2010-03-04 2020-05-13 心血管疾患を処置及び／又は予防するための組成物及び方法 Active JP7136526B2 (ja)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US31044310P	2010-03-04	2010-03-04
US61/310,443		2010-03-04

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2018207855A Division JP2019048843A (ja)	2010-03-04	2018-11-05	心血管疾患を処置及び／又は予防するための組成物及び方法

Publications (3)

Publication Number	Publication Date
JP2020128412A JP2020128412A (ja)	2020-08-27
JP2020128412A5 true JP2020128412A5 (2)	2022-07-20
JP7136526B2 JP7136526B2 (ja)	2022-09-13

Family

ID=44531868

Family Applications (5)

Application Number	Title	Priority Date	Filing Date
JP2012556265A Active JP6327497B2 (ja)	2010-03-04	2011-03-04	心血管疾患を処置及び／又は予防するための組成物及び方法
JP2016183057A Pending JP2017025089A (ja)	2010-03-04	2016-09-20	心血管疾患を処置及び／又は予防するための組成物及び方法
JP2018207855A Pending JP2019048843A (ja)	2010-03-04	2018-11-05	心血管疾患を処置及び／又は予防するための組成物及び方法
JP2020084402A Active JP7136526B2 (ja)	2010-03-04	2020-05-13	心血管疾患を処置及び／又は予防するための組成物及び方法
JP2020124388A Pending JP2020183428A (ja)	2010-03-04	2020-07-21	心血管疾患を処置及び／又は予防するための組成物及び方法

Family Applications Before (3)

Application Number	Title	Priority Date	Filing Date
JP2012556265A Active JP6327497B2 (ja)	2010-03-04	2011-03-04	心血管疾患を処置及び／又は予防するための組成物及び方法
JP2016183057A Pending JP2017025089A (ja)	2010-03-04	2016-09-20	心血管疾患を処置及び／又は予防するための組成物及び方法
JP2018207855A Pending JP2019048843A (ja)	2010-03-04	2018-11-05	心血管疾患を処置及び／又は予防するための組成物及び方法

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
JP2020124388A Pending JP2020183428A (ja)	2010-03-04	2020-07-21	心血管疾患を処置及び／又は予防するための組成物及び方法

Country Status (13)

Country	Link
US (10)	US20110218243A1 (2)
EP (2)	EP2542060B1 (2)
JP (5)	JP6327497B2 (2)
KR (1)	KR20130026428A (2)
AU (1)	AU2011222544A1 (2)
BR (1)	BR112012022336A2 (2)
CA (4)	CA3043081C (2)
ES (1)	ES2750365T3 (2)
MX (1)	MX337315B (2)
PH (3)	PH12012501755A1 (2)
RU (3)	RU2606853C2 (2)
SG (1)	SG183883A1 (2)
WO (1)	WO2011109724A1 (2)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2010028067A1 (en)	2008-09-02	2010-03-11	Amarin Corporation Plc	Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
SG175390A1 (en)	2009-04-29	2011-12-29	Amarin Corp Plc	Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
PT3278665T (pt)	2009-04-29	2020-11-19	Amarin Pharmaceuticals Ie Ltd	Composição farmacêutica estável e métodos de utilização das mesmas
CN106074486A (zh)	2009-06-15	2016-11-09	阿马里纳药物爱尔兰有限公司	在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl‑c水平的组合物和方法
US20110071176A1 (en)	2009-09-23	2011-03-24	Amarin Pharma, Inc.	Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
RU2606853C2 (ru) *	2010-03-04	2017-01-10	Амарин Фармасьютикалз Айрлэнд Лимитед (Апил)	Композиции и способы лечения и/или предотвращения сердечно-сосудистого заболевания
NZ778131A (en)	2010-11-29	2023-03-31	Amarin Pharmaceuticals Ie Ltd	Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en)	2010-11-29	2023-08-01	Amarin Pharmaceuticals Ireland Limited	Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11291643B2 (en)	2011-11-07	2022-04-05	Amarin Pharmaceuticals Ireland Limited	Methods of treating hypertriglyceridemia
EP2775837A4 (en) *	2011-11-07	2015-10-28	Amarin Pharmaceuticals Ie Ltd	METHODS OF TREATING HYPERTRIGLYCERIDEMIA
ES2891473T3 (es) *	2012-01-06	2022-01-28	Amarin Pharmaceuticals Ie Ltd	Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto
EP2861227A4 (en) *	2012-06-17	2016-01-27	Matinas Biopharma Inc	OMEGA-3 PENTAIC ACID COMPOSITIONS AND METHODS OF USE
US20140005264A1 (en) *	2012-06-29	2014-01-02	Amarin Pharmaceuticals Ireland Limited	Methods of treating pediatric metabolic syndrome
WO2014004993A2 (en) *	2012-06-29	2014-01-03	Amarin Pharmaceuticals Ireland Limited	Methods of reducing ldl-p
EP4338805B1 (en)	2012-06-29	2025-06-04	Amarin Pharmaceuticals Ireland Limited	Eicosapentaenoic acid ethyl ester for use in reducing the risk of non-fatal myocardial infarction in a subject on statin therapy
KR20150098611A (ko) *	2012-10-23	2015-08-28	디킨 유니버시티	트리글리세라이드를 감소시키기 위한 방법
WO2014074552A2 (en)	2012-11-06	2014-05-15	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US9629820B2 (en)	2012-12-24	2017-04-25	Qualitas Health, Ltd.	Eicosapentaenoic acid (EPA) formulations
US10123986B2 (en)	2012-12-24	2018-11-13	Qualitas Health, Ltd.	Eicosapentaenoic acid (EPA) formulations
US9814733B2 (en)	2012-12-31	2017-11-14	A,arin Pharmaceuticals Ireland Limited	Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en)	2012-12-31	2014-07-03	Amarin Pharmaceuticals Ireland Limited	Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US20140221676A1 (en) *	2013-02-06	2014-08-07	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for treating and/or preventing cardiovascular disease
US9452151B2 (en)	2013-02-06	2016-09-27	Amarin Pharmaceuticals Ireland Limited	Methods of reducing apolipoprotein C-III
US9624492B2 (en)	2013-02-13	2017-04-18	Amarin Pharmaceuticals Ireland Limited	Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en)	2013-02-19	2017-05-30	The Regents Of The University Of Colorado	Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en)	2013-03-14	2016-03-15	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) *	2013-03-15	2014-09-18	Amarin Pharmaceuticals Ireland Limited	Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en)	2013-06-06	2021-04-06	Amarin Pharmaceuticals Ireland Limited	Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en)	2013-09-04	2015-03-05	Amarin Pharmaceuticals Ireland Limited	Methods of treating or preventing prostate cancer
US9585859B2 (en)	2013-10-10	2017-03-07	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
WO2015066512A1 (en) *	2013-10-31	2015-05-07	Amarin Pharmaceuticals Ireland Limited	Methods of treating hypertriglyceridemia
US10561631B2 (en)	2014-06-11	2020-02-18	Amarin Pharmaceuticals Ireland Limited	Methods of reducing RLP-C
WO2015195662A1 (en)	2014-06-16	2015-12-23	Amarin Pharmaceuticals Ireland Limited	Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
US10406130B2 (en)	2016-03-15	2019-09-10	Amarin Pharmaceuticals Ireland Limited	Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
WO2018213663A1 (en)	2017-05-19	2018-11-22	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US11058661B2 (en)	2018-03-02	2021-07-13	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
KR20210110890A (ko)	2018-09-24	2021-09-09	애머린 파마슈티칼스 아일랜드 리미티드	대상체에서 심혈관 사건의 위험도를 감소시키는 방법
US12427134B2 (en)	2019-11-12	2025-09-30	Amarin Pharmaceuticals Ireland Limited	Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter
AU2022263358A1 (en) *	2021-04-21	2023-11-30	Amarin Pharmaceuticals Ireland Limited	Methods of reducing the risk of heart failure
CN113346980B (zh) *	2021-08-02	2023-08-11	浙江国利信安科技有限公司	用于消息转发的方法、电子设备和计算机存储介质

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4377526A (en) *	1981-05-15	1983-03-22	Nippon Suisan Kaisha, Ltd.	Method of purifying eicosapentaenoic acid and its esters
US4526902A (en) *	1983-10-24	1985-07-02	Century Laboratories, Inc.	Combined fatty acid composition for treatment or prophylaxis of thrombo-embolic conditions
US4920098A (en) *	1986-09-17	1990-04-24	Baxter International Inc.	Nutritional support or therapy for individuals at risk or under treatment for atherosclerotic vascular, cardiovascular, and/or thrombotic diseases
US5252333A (en) *	1987-04-27	1993-10-12	Scotia Holdings Plc	Lithium salt-containing pharmaceutical compositions
US5198468A (en) *	1987-06-24	1993-03-30	Efamol Holdings Plc	Essential fatty acid composition
GB8819110D0 (en) *	1988-08-11	1988-09-14	Norsk Hydro As	Antihypertensive drug & method for production
US5116871A (en) *	1988-09-13	1992-05-26	Efamol Holdings Plc	Fatty acid therapy and compositions for the treatment of myalgic encephalomyelitis
US4935243A (en) *	1988-12-19	1990-06-19	Pharmacaps, Inc.	Chewable, edible soft gelatin capsule
JP2839276B2 (ja) *	1989-01-23	1998-12-16	日本分光工業株式会社	超臨界流体抽出・分離方法及び装置
US5457130A (en) *	1989-03-20	1995-10-10	Cancer Research Campaign Technology Limited	Eicosapentaenoic acid used to treat cachexia
GB9012651D0 (en) *	1990-06-06	1990-07-25	Efamol Holdings	Essential fatty acid treatment
US5215630A (en) *	1991-06-04	1993-06-01	Nippon Suisan Kaisha, Ltd.	Method of purifying eicosapentaenoic acid or the ester derivative thereof by fractional distillation
DE4133694C2 (de) *	1991-10-11	1993-10-07	Fresenius Ag	Verwendung einer Emulsion mit mehrfach ungesättigten Fettsären zur i.v.-Verabreichung zur Behandlung von Hauterkrankungen
JP3400466B2 (ja) *	1991-10-28	2003-04-28	日本水産株式会社	高純度エイコサペンタエン酸またはそのエステルの製造方法
JPH0649479A (ja) *	1992-07-28	1994-02-22	Maruha Corp	ω−３不飽和脂肪酸系化合物の安定化法
GB9217780D0 (en) *	1992-08-21	1992-10-07	Efamol Holdings	Fatty acid treatment
US5888541A (en) *	1992-08-21	1999-03-30	Scotia Holdings Plc	Fatty acid treatment
GB9403857D0 (en) *	1994-03-01	1994-04-20	Scotia Holdings Plc	Fatty acid derivatives
US5760081A (en) *	1994-05-10	1998-06-02	The General Hospital Corporation	Omega 3 fatty acids in the prevention of ventricular fibrillation
AU711482B2 (en) *	1994-06-28	1999-10-14	Scotia Holdings Plc	Compositions for treatment of diabetic complications
IT1274734B (it) *	1994-08-25	1997-07-24	Prospa Bv	Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti
MY118354A (en) *	1995-05-01	2004-10-30	Scarista Ltd	1,3-propane diol derivatives as bioactive compounds
JPH0959206A (ja) *	1995-08-25	1997-03-04	Nippon Oil & Fats Co Ltd	エイコサペンタエン酸およびエイコサペンタエン酸エステルの製造方法
GB9519661D0 (en) *	1995-09-27	1995-11-29	Scotia Holdings Plc	Fatty acid treatment
US5861399A (en) *	1996-07-17	1999-01-19	Heart Care Partners	Methods and compositions for the rapid and enduring relief of inadequate myocardial function
US20020055539A1 (en) *	1996-10-02	2002-05-09	Bockow Barry I.	Compositions and methods for treating cardiovascular conditions
CN1109543C (zh) *	1996-10-11	2003-05-28	斯卡里斯塔有限公司	包括二十碳五烯酸和/或十八碳四烯酸的药物制剂
US6531150B1 (en) *	1997-10-30	2003-03-11	Morishita Jintan Co., Ltd.	Encapsulated unsaturated fatty acid substance and method for producing the same
GB9901809D0 (en) *	1999-01-27	1999-03-17	Scarista Limited	Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
US20030104048A1 (en) *	1999-02-26	2003-06-05	Lipocine, Inc.	Pharmaceutical dosage forms for highly hydrophilic materials
US6193999B1 (en) *	1999-03-01	2001-02-27	Banner Pharmacaps, Inc.	Gum acacia substituted soft gelatin capsules
DK1072198T3 (da) *	1999-07-28	2008-09-22	Swiss Caps Rechte & Lizenzen	Præparat til anvendelse som medikament og/eller ernæringstilskud
AU6813700A (en) *	1999-08-30	2001-03-26	Ocean Nutrition Canada Ltd.	A nutritional supplement for lowering serum triglyceride and cholesterol levels
JP4170542B2 (ja) *	1999-11-18	2008-10-22	日油株式会社	高度不飽和脂肪酸誘導体の製造方法及び高純度エイコサペンタエン酸誘導体
ITMI20010129A1 (it) *	2001-01-25	2002-07-25	Pharmacia & Upjohn Spa	Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
ATE291910T1 (de) *	2001-05-30	2005-04-15	Laxdale Ltd	Verwendung von coenzym q (ubiquinone) und eikosapentaensäure (epa) für die behandlung von non-hodgkin's lymphoma und psychiatrischen oder neurologischen erkrankungen
ITMI20012384A1 (it) *	2001-11-12	2003-05-12	Quatex Nv	Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori
US20030166614A1 (en) *	2002-03-01	2003-09-04	Harrison Stanley F.	Method for reducing cholesterol and triglycerides
WO2004017958A1 (ja) *	2002-08-20	2004-03-04	Nikken Chemicals Co., Ltd.	軟カプセル剤
KR20050083960A (ko) *	2002-11-22	2005-08-26	닛폰 스이산 가부시키가이샤	고도 불포화 지방산, 그 염, 또는 그 에스테르를 함유하는외용 조성물
EP1711173A2 (en) *	2003-12-31	2006-10-18	Igennus Limited	Formulation containing an eicosapentaenoic acid or an ester thereof and a triterpene or ester thereof
US20100021555A1 (en) *	2004-10-15	2010-01-28	Karl Geiringer	Compositions containing high omega-3 and low saturated fatty acid levels
US20070191467A1 (en) *	2004-12-06	2007-08-16	Reliant Pharmaceutical, Inc.	Statin and omega-3 fatty acids for lipid therapy
CA2589654C (en) *	2004-12-06	2016-02-16	Reliant Pharmaceuticals, Inc.	Omega-3 fatty acids and dyslipidemic agent for lipid therapy
US20060135610A1 (en) *	2004-12-22	2006-06-22	Bortz Jonathan D	Cardiovascular compositions
GB2421909A (en) *	2004-12-23	2006-07-12	Laxdale Ltd	Pharmaceutical compositions comprising EPA and methods of use
US20070104779A1 (en) *	2005-11-07	2007-05-10	Rongen Roelof M	Treatment with omega-3 fatty acids and products thereof
NZ569068A (en) *	2005-12-20	2011-11-25	Cenestra Llc	Omega 3 fatty acid formulations of EPA and DHA
EP1982710B1 (en) *	2006-02-07	2013-12-18	Mochida Pharmaceutical Co., Ltd.	Composition for prevention of recurrence of stroke
CA2653787C (en) *	2006-05-31	2016-06-21	Mochida Pharmaceutical Co., Ltd.	Composition for preventing the occurrence of cardiovascular event in multiple risk patient
CA2656311C (en) *	2006-07-05	2016-06-21	Photonz Corporation Limited	Ultra pure epa and polar lipids produced in largely heterotrophic culture
WO2008012329A2 (en) *	2006-07-28	2008-01-31	V. Mane Fils	Seamless capsules containing high amounts of polyunsaturated fatty acids and a flavouring component
US20080125490A1 (en) *	2006-11-03	2008-05-29	My Svensson	Treatment and prevention of cardiovascular disease in patients with chronic kidney disease by administering Omega-3 Fatty Acids
KR101383006B1 (ko) *	2009-02-10	2014-04-08	아마린 파마, 인크.	고중성지방혈증 치료 방법
CN106074486A (zh) *	2009-06-15	2016-11-09	阿马里纳药物爱尔兰有限公司	在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl‑c水平的组合物和方法
RU2606853C2 (ru) *	2010-03-04	2017-01-10	Амарин Фармасьютикалз Айрлэнд Лимитед (Апил)	Композиции и способы лечения и/или предотвращения сердечно-сосудистого заболевания

2011
- 2011-03-04 RU RU2012142181A patent/RU2606853C2/ru active
- 2011-03-04 EP EP11751431.5A patent/EP2542060B1/en active Active
- 2011-03-04 CA CA3043081A patent/CA3043081C/en active Active
- 2011-03-04 PH PH1/2012/501755A patent/PH12012501755A1/en unknown
- 2011-03-04 SG SG2012065215A patent/SG183883A1/en unknown
- 2011-03-04 EP EP19190599.1A patent/EP3583849A1/en not_active Withdrawn
- 2011-03-04 ES ES11751431T patent/ES2750365T3/es active Active
- 2011-03-04 RU RU2016129266A patent/RU2728825C2/ru active
- 2011-03-04 CA CA3066588A patent/CA3066588C/en active Active
- 2011-03-04 JP JP2012556265A patent/JP6327497B2/ja active Active
- 2011-03-04 CA CA3147657A patent/CA3147657C/en active Active
- 2011-03-04 KR KR1020127024878A patent/KR20130026428A/ko not_active Ceased
- 2011-03-04 BR BR112012022336-4A patent/BR112012022336A2/pt not_active Application Discontinuation
- 2011-03-04 AU AU2011222544A patent/AU2011222544A1/en not_active Abandoned
- 2011-03-04 US US13/040,977 patent/US20110218243A1/en not_active Abandoned
- 2011-03-04 CA CA2792090A patent/CA2792090C/en active Active
- 2011-03-04 MX MX2012010253A patent/MX337315B/es active IP Right Grant
- 2011-03-04 WO PCT/US2011/027218 patent/WO2011109724A1/en not_active Ceased
2013
- 2013-08-28 US US14/012,625 patent/US20140128464A1/en not_active Abandoned
2015
- 2015-05-28 US US14/723,799 patent/US20150335607A1/en not_active Abandoned
2016
- 2016-09-20 JP JP2016183057A patent/JP2017025089A/ja active Pending
2017
- 2017-01-23 US US15/413,093 patent/US20170128406A1/en not_active Abandoned
2018
- 2018-04-19 PH PH12018500843A patent/PH12018500843B1/en unknown
- 2018-11-05 JP JP2018207855A patent/JP2019048843A/ja active Pending
2019
- 2019-05-06 US US16/404,558 patent/US20200297681A1/en not_active Abandoned
2020
- 2020-05-13 JP JP2020084402A patent/JP7136526B2/ja active Active
- 2020-07-08 US US16/923,311 patent/US20200360330A1/en not_active Abandoned
- 2020-07-17 RU RU2020123679A patent/RU2020123679A/ru unknown
- 2020-07-21 JP JP2020124388A patent/JP2020183428A/ja active Pending
2021
- 2021-01-19 US US17/151,956 patent/US20210260016A1/en not_active Abandoned
- 2021-01-21 US US17/154,357 patent/US20210386701A1/en not_active Abandoned
- 2021-04-06 PH PH12021550756A patent/PH12021550756A1/en unknown
- 2021-12-03 US US17/457,579 patent/US20220323393A1/en not_active Abandoned
2024
- 2024-03-13 US US18/603,789 patent/US20240216322A1/en not_active Abandoned

Publication	Publication Date	Title
JP2020128412A5 (2)	2022-07-20
JP2019048843A5 (2)	2022-02-17
JP2021534185A5 (2)	2022-08-22
HRP20210686T1 (hr)	2021-06-11	Pripravci i postupci za liječenje moždanog udara kod subjekta na istodobnoj terapiji statinom
JP2893460B2 (ja)	1999-05-24	脂肪酸による治療および組成物
EP2664328B1 (en)	2018-11-21	Omega3 fatty acid compound preparation
CN102843922B (zh)	2015-12-16	硝基脂肪酸–认知减退的神经保护和/或抑制
JP6173437B2 (ja)	2017-08-02	スタチン及びω−３脂肪酸の組成物
RU2017121277A (ru)	2018-12-19	Фармацевтические композиции, содержащие epa и сердечно-сосудистое средство, и способы их применения
RU2018116572A (ru)	2018-10-23	Композиции омега-3 полиненасыщенных жирных кислот в форме свободной кислоты, обогащенные DPA
JP2013521310A5 (2)	2014-04-17
RU2016129266A (ru)	2018-12-07	Композиции и способы лечения и/или предотвращения сердечно-сосудистого заболевания
JP2010116414A (ja)	2010-05-27	心血管事象を予防するための必須脂肪酸
WO2007007686A1 (ja)	2007-01-18	心血管イベント発症予防用組成物
JP2023153863A (ja)	2023-10-18	１５－ｈｅｐｅを含む組成物及びその使用方法
JP2012516852A5 (2)	2013-03-21
JP2003508484A5 (2)	2005-05-26
WO2012112531A1 (en)	2012-08-23	Statin and omega 3 fatty acids (epa, dha and dpa) for use in cardiovascular diseases
JP2022031813A (ja)	2022-02-22	１５－ｈｅｐｅを含む組成物、およびそれを用いて線維症を処置または防止する方法
SG181446A1 (en)	2012-07-30	Combination composition useful for treating cardiovascular diseases
JP6469261B2 (ja)	2019-02-13	多価不飽和遊離脂肪酸を含むミリカプセル製剤
JP2009544701A (ja)	2009-12-17	オメガ３脂肪酸を含む組成物、ならびに末梢動脈障害および間欠性跛行を処置するためのそれらの使用
EP2674157A1 (en)	2013-12-18	Therapeutic agent for diastolic congestive heart failure
MX2011001419A (es)	2011-05-25	Tratamiento a largo plazo de deficiencia cardiaca sintomatica.
JP2024526939A5 (2)	2024-07-29